CVS Health Corporation (NYSE:CVS) was upgraded by equities research analysts at Vetr from a “hold” rating to a “buy” rating in a research note issued on Monday. The brokerage currently has a $94.49 target price on the pharmacy operator’s stock. Vetr‘s price target would indicate a potential upside of 9.36% from the stock’s current price.

Several other equities analysts have also commented on the company. Credit Suisse Group AG reiterated an “outperform” rating and set a $110.00 price objective (down from $115.00) on shares of CVS Health Corporation in a research report on Tuesday, October 4th. Robert W. Baird reduced their price objective on CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating on the stock in a research report on Monday, October 3rd. Leerink Swann reiterated an “outperform” rating and set a $105.00 price objective (down from $110.00) on shares of CVS Health Corporation in a research report on Sunday, October 2nd. Mizuho reiterated a “buy” rating and set a $111.00 price objective on shares of CVS Health Corporation in a research report on Friday, September 30th. Finally, Morgan Stanley reiterated a “hold” rating and set a $104.00 price objective on shares of CVS Health Corporation in a research report on Monday, September 12th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. CVS Health Corporation currently has a consensus rating of “Buy” and an average price target of $112.40.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Shares of CVS Health Corporation (NYSE:CVS) opened at 86.40 on Monday. The firm has a 50-day moving average price of $91.41 and a 200-day moving average price of $96.91. The company has a market capitalization of $92.12 billion, a P/E ratio of 19.88 and a beta of 0.83. CVS Health Corporation has a one year low of $85.89 and a one year high of $106.67.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings data on Tuesday, August 2nd. The pharmacy operator reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. The firm had revenue of $43.70 billion for the quarter, compared to analyst estimates of $44.28 billion. CVS Health Corporation had a return on equity of 15.86% and a net margin of 2.88%. The company’s revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.19 EPS. Equities analysts forecast that CVS Health Corporation will post $5.86 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 3rd. Shareholders of record on Monday, October 24th will be issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health Corporation’s payout ratio is 39.08%.

Several hedge funds have recently bought and sold shares of CVS. Acrospire Investment Management LLC raised its stake in CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock worth $102,000 after buying an additional 900 shares during the last quarter. MU Investments Co. Ltd. increased its position in CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock worth $109,000 after buying an additional 440 shares during the period. Pinkerton Retirement Specialists LLC increased its position in CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock worth $110,000 after buying an additional 1,112 shares during the period. D Orazio & Associates Inc. increased its position in CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock worth $111,000 after buying an additional 100 shares during the period. Finally, Cantab Capital Partners LLP increased its position in CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock worth $113,000 after buying an additional 924 shares during the period. 80.96% of the stock is owned by institutional investors and hedge funds.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.